A healthcare focused venture capital firm based in China, with offices in Shanghai and Beijing, makes venture investments in early & growth stage companies and PIPE deals. The firm is flexible regarding the investment size; the firm can invest anywhere from several hundred thousand dollars up to USD 10 million or more. The firm generally invests in global companies with current investments mostly in US and China. The firm is actively seeking new investment opportunities.

The firm invests opportunistically in the life sciences. The firm is interested in biopharmaceuticals, medical devices, diagnostics, and mobile/digital health. Within therapeutics, the firm is most interested in oncology and neurology. The firm considers all molecules and biologics, including biosimilars and reformulated drugs. In terms of stage of development, the firm looks for products in early to late stages of clinical trials. The firm generally looks for devices in later stages of development or close to market.

The firm invests in both private and public companies, and has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm with a new second fund closed in early 2020, invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe currently manages three funds, the newest of which closed in 2020 and focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment vehicle based in Western Europe is looking to invest in therapeutics companies as well as companies developing digital therapeutics or therapeutic-enabling technologies. The firm is primarily interested in early stage, pre-clinical breakthrough technologies and, especially for digital-based companies, capital efficient business models. While the firm has invested primarily within Western Europe up until now, The firm is willing to consider companies in other geographies if they find the technology compelling. For a first investment, the firm invests, on average, 2M, but can invest smaller or larger amounts, depending on the company and its needs.

The firm is looking for companies in the broader therapeutics space. The firm is interested not only in more traditional therapeutics technologies, but also in digital therapeutics and digital therapeutic-enabling technologies, drug development platforms, including digital and genomics-based drug development technologies, and in cell and gene therapy manufacturing technologies. The firm has historically invested primarily in technologies relating to oncology, but will consider any indication.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and developer of medical technologies headquartered in Asia with a subsidiary located in USA looks for new in-licensing or investment opportunities in cutting-edge medical device innovations from North America, Asia, and Europe, with no set cap on investment size.
With vertical integration of experienced medical professionals, talented engineers, and international infrastructure, the firm is dedicated to developing high value and high impact medical devices.

Focusing on minimally invasive surgical devices and healthcare information technologies, the firm invests in companies at any stage of development, from ideation, early product design, prototyping, preclinical testing, clinical trials to commercialization. The firm prefers disease states with sizable patient population, including but not limited to cardiovascular or peripheral vascular disease, orthopedics, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery.

The firm is looking for collaborations with competent entrepreneurs, physicians, companies and investors and willing to lead and co-invest in med-tech companies to develop novel solutions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm founded in the USA invests in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers that companies are located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. The firm also has an early-stage focused fund through which the firm makes angel investments into high potential, early-stage companies. With this fund, the firm typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Digital Health, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to their early-stage fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over RMB 29 billion (USD $4.5 billion). Typical equity allocations range from US$2-6 million in an early-stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, the US, and the EU.

The firm currently focuses on pharmaceuticals, medical devices, and IVD tools in late clinical development or early preclinical stage with high entry battier and market potential.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of the joint venture and strategic partnerships in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.